174 related articles for article (PubMed ID: 3662564)
1. Thin malignant melanomas with regression and metastases.
Ronan SG; Eng AM; Briele HA; Shioura NN; Das Gupta TK
Arch Dermatol; 1987 Oct; 123(10):1326-30. PubMed ID: 3662564
[TBL] [Abstract][Full Text] [Related]
2. Regression in thin malignant melanoma. Microscopic diagnosis and prognostic importance.
Cooper PH; Wanebo HJ; Hagar RW
Arch Dermatol; 1985 Sep; 121(9):1127-31. PubMed ID: 4037837
[TBL] [Abstract][Full Text] [Related]
3. Cutaneous melanomas that defy conventional prognostic indicators.
McCarthy WH; Shaw HM; McCarthy SW; Rivers JK; Thompson JF
Semin Oncol; 1996 Dec; 23(6):709-13. PubMed ID: 8970591
[TBL] [Abstract][Full Text] [Related]
4. Thin primary cutaneous malignant melanoma: a prognostic tree for 10-year metastasis is more accurate than American Joint Committee on Cancer staging.
Gimotty PA; Guerry D; Ming ME; Elenitsas R; Xu X; Czerniecki B; Spitz F; Schuchter L; Elder D
J Clin Oncol; 2004 Sep; 22(18):3668-76. PubMed ID: 15302909
[TBL] [Abstract][Full Text] [Related]
5. Tumour regression does not increase the risk of sentinel node involvement in thin melanomas.
Cecchi R; Pavesi M; Buralli L; Innocenti S; De Gaudio C
Chir Ital; 2008; 60(2):257-60. PubMed ID: 18689175
[TBL] [Abstract][Full Text] [Related]
6. The correlation of regression in primary melanoma with sentinel lymph node status.
Kaur C; Thomas RJ; Desai N; Green MA; Lovell D; Powell BW; Cook MG
J Clin Pathol; 2008 Mar; 61(3):297-300. PubMed ID: 17675538
[TBL] [Abstract][Full Text] [Related]
7. Identification of histological features associated with metastatic potential in thin (<1.0 mm) cutaneous melanoma with metastases. A study on behalf of the EORTC Melanoma Group.
Cook MG; Spatz A; Bröcker EB; Ruiter DJ
J Pathol; 2002 Jun; 197(2):188-93. PubMed ID: 12015742
[TBL] [Abstract][Full Text] [Related]
8. Sentinel lymph node biopsy for the T1 (thin) melanoma: is it necessary?
Nahabedian MY; Tufaro AP; Manson PN
Ann Plast Surg; 2003 Jun; 50(6):601-6. PubMed ID: 12783009
[TBL] [Abstract][Full Text] [Related]
9. [Melanoma in organ transplant patients].
Lévêque L; Dalac S; Dompmartin A; Louvet S; Euvrard S; Catteau B; Hazan M; Schollhamer M; Aubin F; Dreno B; Daguin P; Chevrant-Breton J; Frances C; Bismuth MJ; Tanter Y; Lambert D
Ann Dermatol Venereol; 2000 Feb; 127(2):160-5. PubMed ID: 10739973
[TBL] [Abstract][Full Text] [Related]
10. Sentinel lymph node micrometastasis and other histologic factors that predict outcome in patients with thicker melanomas.
Cherpelis BS; Haddad F; Messina J; Cantor AB; Fitzmorris K; Reintgen DS; Fenske NA; Glass LF
J Am Acad Dermatol; 2001 May; 44(5):762-6. PubMed ID: 11312421
[TBL] [Abstract][Full Text] [Related]
11. Melanomas in renal transplant recipients.
Le Mire L; Hollowood K; Gray D; Bordea C; Wojnarowska F
Br J Dermatol; 2006 Mar; 154(3):472-7. PubMed ID: 16445778
[TBL] [Abstract][Full Text] [Related]
12. [Verrucous malignant melanoma (spontaneous regression and simultaneous development of a secondary tumor)].
Mahrle C; Bolling R; Gartmann H
Z Hautkr; 1977 Sep; 52(17):897-905. PubMed ID: 910537
[TBL] [Abstract][Full Text] [Related]
13. The current surgical treatment of primary malignant melanoma of the skin.
Bognár J; Nagy P; Kádár E; Bajtai A; Mayer A; Daróczy J; Jakab F
Acta Chir Hung; 1997; 36(1-4):37-8. PubMed ID: 9408278
[TBL] [Abstract][Full Text] [Related]
14. Prognosis for patients with thin cutaneous melanoma: long-term survival data from New South Wales Central Cancer Registry and the Sydney Melanoma Unit.
McKinnon JG; Yu XQ; McCarthy WH; Thompson JF
Cancer; 2003 Sep; 98(6):1223-31. PubMed ID: 12973846
[TBL] [Abstract][Full Text] [Related]
15. An evidence base for reconsidering current follow-up guidelines for patients with cutaneous melanoma less than 0.5 mm thick at diagnosis.
Einwachter-Thompson J; MacKie RM
Br J Dermatol; 2008 Aug; 159(2):337-41. PubMed ID: 18510665
[TBL] [Abstract][Full Text] [Related]
16. Favorable prognosis for malignant melanomas associated with acquired melanocytic nevi.
Friedman RJ; Rigel DS; Kopf AW; Lieblich L; Lew R; Harris MN; Roses DF; Gumport SL; Ragaz A; Waldo E; Levine J; Levenstein M; Koenig R; Bart RS; Trau H
Arch Dermatol; 1983 Jun; 119(6):455-62. PubMed ID: 6859885
[TBL] [Abstract][Full Text] [Related]
17. Spontaneous regression of malignant melanoma: a review of the literature on incidence, clinical features, and possible mechanisms.
Nathanson
Natl Cancer Inst Monogr; 1976 Nov; 44():67-76. PubMed ID: 799762
[TBL] [Abstract][Full Text] [Related]
18. The natural history of malignant melanoma of the choroid: small vs large tumors.
Davidorf FH; Lang JR
Trans Sect Ophthalmol Am Acad Ophthalmol Otolaryngol; 1975; 79(2):OP310-20. PubMed ID: 1145955
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of DNA ploidy and degree of DNA abnormality in benign and malignant melanocytic lesions of the skin using video imaging.
Pilch H; Günzel S; Schäffer U; Tanner B; Heine M
Cancer; 2000 Mar; 88(6):1370-7. PubMed ID: 10717619
[TBL] [Abstract][Full Text] [Related]
20. Spontaneous regression of metastases from malignant melanoma: a case report.
Kalialis LV; Drzewiecki KT; Mohammadi M; Mehlsen AB; Klyver H
Melanoma Res; 2008 Aug; 18(4):279-83. PubMed ID: 18626313
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
